Merck's Oncology Strength: Beating Wall Street Again

Dear Seeking Alpha readers, I want to start by apologizing that since the publication of my article "Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade)," Merck & Co., Inc. (NYSE: MRKWith over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutical companies.Al ...